EHHB was marketed in France in a 5 mg/mL oil solution in ampoules for intramuscular injection at regular intervals, for instance once every few weeks. Use of EHHB for feminizing hormone therapy in transgender women has been reported. A combination of 3 mg EHHB, 75 mg hydroxyprogesterone caproate, and 100 mg testosterone hexahydrobenzoate in 2 mL oil solution provided in ampoules has been marketed under the brand name Trinestril AP in Brazil. Its indications include menopausal hormone therapy and the treatment of functional uterine bleeding. The combination is administered typically once per month by intramuscular injection.
Estradiol hexahydrobenzoate
Estradiol diundecylate
Estradiol monopropionate
Testosterone hexahydrobenzoate
Estradiol dibutyrate
Estradiol palmitate
Estriol glucuronide
Polyestriol phosphate